FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206987172> ?p ?o ?g. }

• W4206987172 abstract "5-Lipoxygenase (5-LO) is the key enzyme in the formation of pro-inflammatory leukotrienes (LT) which play an important role in a number of inflammatory diseases. Accordingly, 5-LO inhibitors are frequently used to study the role of 5-LO and LT in models of inflammation and cancer. Interestingly, the therapeutic efficacy of these inhibitors is highly variable. Here we show that the frequently used 5-LO inhibitors AA-861, BWA4C, C06, CJ-13,610 and the FDA approved compound zileuton as well as the pan-LO inhibitor nordihydroguaiaretic acid interfere with prostaglandin E2 (PGE2) release into the supernatants of cytokine-stimulated (TNFα/IL-1β) HeLa cervix carcinoma, A549 lung cancer as well as HCA-7 colon carcinoma cells with similar potencies compared to their LT inhibitory activities (IC50 values ranging from 0.1-9.1 µM). In addition, AA-861, BWA4C, CJ-13,610 and zileuton concentration-dependently inhibited bacterial lipopolysaccharide triggered prostaglandin (PG) release into human whole blood. Western Blot analysis revealed that inhibition of expression of enzymes involved in PG synthesis was not part of the underlying mechanism. Also, liberation of arachidonic acid which is the substrate for PG synthesis as well as PGH2 and PGE2 formation were not impaired by the compounds. However, accumulation of intracellular PGE2 was found in the inhibitor treated HeLa cells suggesting inhibition of PG export as major mechanism. Further, experiments showed that the PG exporter ATP-binding cassette transporter multidrug resistance protein 4 (MRP-4) is targeted by the inhibitors and may be involved in the 5-LO inhibitor-mediated PGE2 inhibition. In conclusion, the pharmacological effects of a number of 5-LO inhibitors are compound-specific and involve the potent inhibition of PGE2 export. Results from experimental models on the role of 5-LO in inflammation and pain using 5-LO inhibitors may be misleading and their use as pharmacological tools in experimental models has to be revisited. In addition, 5-LO inhibitors may serve as new scaffolds for the development of potent prostaglandin export inhibitors." @default.
• W4206987172 created "2022-01-26" @default.
• W4206987172 creator A5000407855 @default.
• W4206987172 creator A5008447327 @default.
• W4206987172 creator A5019047498 @default.
• W4206987172 creator A5022782467 @default.
• W4206987172 creator A5038305604 @default.
• W4206987172 creator A5040043299 @default.
• W4206987172 creator A5047560431 @default.
• W4206987172 creator A5051358933 @default.
• W4206987172 creator A5062995444 @default.
• W4206987172 creator A5078612562 @default.
• W4206987172 creator A5082078699 @default.
• W4206987172 creator A5090122865 @default.
• W4206987172 creator A5091269791 @default.
• W4206987172 date "2022-01-21" @default.
• W4206987172 modified "2023-10-14" @default.
• W4206987172 title "Inhibitors of Human 5-Lipoxygenase Potently Interfere With Prostaglandin Transport" @default.
• W4206987172 cites W1544399526 @default.
• W4206987172 cites W1574721641 @default.
• W4206987172 cites W1963577773 @default.
• W4206987172 cites W1973141368 @default.
• W4206987172 cites W1975272363 @default.
• W4206987172 cites W1989342810 @default.
• W4206987172 cites W1997384637 @default.
• W4206987172 cites W1998232267 @default.
• W4206987172 cites W2019774786 @default.
• W4206987172 cites W2023524350 @default.
• W4206987172 cites W2024263598 @default.
• W4206987172 cites W2024301445 @default.
• W4206987172 cites W2025563699 @default.
• W4206987172 cites W2025826180 @default.
• W4206987172 cites W2031685248 @default.
• W4206987172 cites W2036165468 @default.
• W4206987172 cites W2036299072 @default.
• W4206987172 cites W2043827616 @default.
• W4206987172 cites W2045329975 @default.
• W4206987172 cites W2053017995 @default.
• W4206987172 cites W2060692647 @default.
• W4206987172 cites W2069598355 @default.
• W4206987172 cites W2077169693 @default.
• W4206987172 cites W2085588489 @default.
• W4206987172 cites W2094552994 @default.
• W4206987172 cites W2108742399 @default.
• W4206987172 cites W2129935236 @default.
• W4206987172 cites W2135676145 @default.
• W4206987172 cites W2138259388 @default.
• W4206987172 cites W2154695733 @default.
• W4206987172 cites W2171958164 @default.
• W4206987172 cites W2186139127 @default.
• W4206987172 cites W2235016145 @default.
• W4206987172 cites W2255927959 @default.
• W4206987172 cites W2408408842 @default.
• W4206987172 cites W2488648258 @default.
• W4206987172 cites W2537943818 @default.
• W4206987172 doi "https://doi.org/10.3389/fphar.2021.782584" @default.
• W4206987172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35126121" @default.
• W4206987172 hasPublicationYear "2022" @default.
• W4206987172 type Work @default.
• W4206987172 citedByCount "6" @default.
• W4206987172 countsByYear W42069871722022 @default.
• W4206987172 countsByYear W42069871722023 @default.
• W4206987172 crossrefType "journal-article" @default.
• W4206987172 hasAuthorship W4206987172A5000407855 @default.
• W4206987172 hasAuthorship W4206987172A5008447327 @default.
• W4206987172 hasAuthorship W4206987172A5019047498 @default.
• W4206987172 hasAuthorship W4206987172A5022782467 @default.
• W4206987172 hasAuthorship W4206987172A5038305604 @default.
• W4206987172 hasAuthorship W4206987172A5040043299 @default.
• W4206987172 hasAuthorship W4206987172A5047560431 @default.
• W4206987172 hasAuthorship W4206987172A5051358933 @default.
• W4206987172 hasAuthorship W4206987172A5062995444 @default.
• W4206987172 hasAuthorship W4206987172A5078612562 @default.
• W4206987172 hasAuthorship W4206987172A5082078699 @default.
• W4206987172 hasAuthorship W4206987172A5090122865 @default.
• W4206987172 hasAuthorship W4206987172A5091269791 @default.
• W4206987172 hasBestOaLocation W42069871721 @default.
• W4206987172 hasConcept C104317684 @default.
• W4206987172 hasConcept C181199279 @default.
• W4206987172 hasConcept C185592680 @default.
• W4206987172 hasConcept C202751555 @default.
• W4206987172 hasConcept C2776241388 @default.
• W4206987172 hasConcept C2776415932 @default.
• W4206987172 hasConcept C2776889390 @default.
• W4206987172 hasConcept C2777366897 @default.
• W4206987172 hasConcept C2777752497 @default.
• W4206987172 hasConcept C2778078955 @default.
• W4206987172 hasConcept C2778484676 @default.
• W4206987172 hasConcept C2780664492 @default.
• W4206987172 hasConcept C2781370401 @default.
• W4206987172 hasConcept C55493867 @default.
• W4206987172 hasConcept C81729549 @default.
• W4206987172 hasConcept C86803240 @default.
• W4206987172 hasConcept C90342290 @default.
• W4206987172 hasConcept C98274493 @default.
• W4206987172 hasConceptScore W4206987172C104317684 @default.
• W4206987172 hasConceptScore W4206987172C181199279 @default.
• W4206987172 hasConceptScore W4206987172C185592680 @default.
• W4206987172 hasConceptScore W4206987172C202751555 @default.
• W4206987172 hasConceptScore W4206987172C2776241388 @default.

• next